🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

63 results for “Merck KGaA, Darmstadt, Germany” Clear

  1. Miransertib

    Merck KGaA, Darmstadt, Germany

    PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

    phase 2 small molecule terminated

    1 trial

  2. Paclitaxel

    Merck KGaA, Darmstadt, Germany

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Melanoma

    phase 2 mab completed

    1 trial

  4. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Advanced Non-Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  5. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  6. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 mab active

    1 trial

  7. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Pembrolizumab/Vibostolimab coformulation

    Merck KGaA, Darmstadt, Germany

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  9. Raludotatug Deruxtecan (R-DXd)

    Merck KGaA, Darmstadt, Germany

    Gastrointestinal Cancer

    phase 2 mab active

    1 trial

  10. alvimopan

    Merck KGaA, Darmstadt, Germany

    Constipation

    phase 2 small molecule completed

    1 trial

  11. Boserolimab

    Merck KGaA, Darmstadt, Germany

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  12. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  13. Bisoprolol

    Merck KGaA, Darmstadt, Germany

    Hypertension

    approved small molecule completed

    1 trial

  14. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Non-Small-Cell Lung

    approved small molecule completed

    1 trial

  15. Raltegravir

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources